September 12, 2014 (Shareholders Foundation) - An investigation on behalf of investors of Hyperion Therapeutics Inc (NASDAQ:HPTX) shares over potential securities laws violations by Hyperion Therapeutics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Hyperion Therapeutics Inc (NASDAQ:HPTX) concerning whether a series of statements by Hyperion Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Hyperion Therapeutics Inc reported that its annual Total Revenue rose to $42.20 million in 2013 and that its Net Loss of $32.26 million from 2012 turned to a Net Income of $16.63 million in 2013. Shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) grew from $11.16 per share in January 2013 to as high as $31.00 per share in February 2014.

On September 8, 2014 Hyperion Therapeutics Inc (NASDAQ:HPTX) announced that it is terminating development of DiaPep277 for newly diagnosed Type 1 diabetes. Shares of Hyperion Therapeutics Inc (NASDAQ:HPTX) fell from $27.64 per share on September 5, 2014, to as low as $24.55 per share during September 8, 2014.